The accuracy of diagnostic indicators for coeliac disease: A systematic review and meta-analysis.

Martha M C Elwenspoek, Joni Jackson, Rachel O'Donnell, Anthony Sinobas, Sarah Dawson, Hazel Everitt, Peter Gillett, Alastair D Hay, Deborah L Lane, Susan Mallett, Gerry Robins, Jessica C Watson, Hayley E Jones, Penny Whiting

Journal: PloS one 2024;16(10):e0258501

PMID: 34695139

Abstract

BACKGROUND

The prevalence of coeliac disease (CD) is around 1%, but diagnosis is challenged by varied presentation and non-specific symptoms and signs. This study aimed to identify diagnostic indicators that may help identify patients at a higher risk of CD in whom further testing is warranted.

METHODS

International guidance for systematic review methods were followed and the review was registered at PROSPERO (CRD42020170766). Six databases were searched until April 2021. Studies investigating diagnostic indicators, such as symptoms or risk conditions, in people with and without CD were eligible for inclusion. Risk of bias was assessed using the QUADAS-2 tool. Summary sensitivity, specificity, and positive predictive values were estimated for each diagnostic indicator by fitting bivariate random effects meta-analyses.

FINDINGS

191 studies reporting on 26 diagnostic indicators were included in the meta-analyses. We found large variation in diagnostic accuracy estimates between studies and most studies were at high risk of bias. We found strong evidence that people with dermatitis herpetiformis, migraine, family history of CD, HLA DQ2/8 risk genotype, anaemia, type 1 diabetes, osteoporosis, or chronic liver disease are more likely than the general population to have CD. Symptoms, psoriasis, epilepsy, inflammatory bowel disease, systemic lupus erythematosus, fractures, type 2 diabetes, and multiple sclerosis showed poor diagnostic ability. A sensitivity analysis revealed a 3-fold higher risk of CD in first-degree relatives of CD patients.

CONCLUSIONS

Targeted testing of individuals with dermatitis herpetiformis, migraine, family history of CD, HLA DQ2/8 risk genotype, anaemia, type 1 diabetes, osteoporosis, or chronic liver disease could improve case-finding for CD, therefore expediting appropriate treatment and reducing adverse consequences. Migraine and chronic liver disease are not yet included as a risk factor in all CD guidelines, but it may be appropriate for these to be added. Future research should establish the diagnostic value of combining indicators.

Address: The National Institute for Health Research Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.; Bristol Medical School, University of Bristol, Bristol, United Kingdom.; Primary Care Research Centre, University of Southampton, Southampton, United Kingdom.; Paediatric Gastroenterology, Hepatology and Nutrition Department, Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom.; Patient representative, Cambridge, United Kingdom.; Centre for Medical Imaging, University College London, London, United Kingdom.; Department of Gastroenterology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.